Join Growin Stock Community!

Aptevo therapeutics inc.APVO.US Overview

US StockHealthcare
(No presentation for APVO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

APVO AI Insights

APVO Overall Performance

APVO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

APVO Recent Performance

-

Aptevo therapeutics inc.

0.05%

Avg of Sector

-0.31%

S&P500

APVO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

APVO Key Information

APVO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

APVO Profile

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Price of APVO

APVO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

APVO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-28.28
PE Ratio (TTM)
0.00
Forward PE
-
PS Ratio (TTM)
1.61
PB Ratio
0.42
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-28.28
PE Ratio (TTM)
0.00
Forward PE
-
PS Ratio (TTM)
1.61
PB Ratio
0.42
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is APVO's latest earnings report released?

    The most recent financial report for Aptevo therapeutics inc. (APVO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating APVO's short-term business performance and financial health. For the latest updates on APVO's earnings releases, visit this page regularly.

  • How much cash does APVO have?

    At the end of the period, Aptevo therapeutics inc. (APVO) held Total Cash and Cash Equivalents of 21.06M, accounting for 0.78 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is APVO's EPS continuing to grow?

    According to the past four quarterly reports, Aptevo therapeutics inc. (APVO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -40.1. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of APVO?

    Aptevo therapeutics inc. (APVO)'s Free Cash Flow (FCF) for the period is -6.69M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 28.07% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.